The Effect of the Linezolid Dose on the Dynamics of Peripheral Neuropathy Markers and the Development of Hematotoxicity

Read full text Summarise with VIRAT
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Galina Mozhokina1,2, Anastasia Gaida1, Eleonora Pereverzeva2, Sophia Yazerian2, Anastasia Samoilova1, Irina Vasilyeva1,3 1Federal State Budgetary Institution “National Medical Research Center for Phthisiopulmonology and Infectious Diseases” of the Ministry of Health of the Russian Federation, Scientific Department of Diagnostics and Differential Diagnosis of Tuberculosis and Combined Infections, 2Gause Institute of New Antibiotics, 3Department of Phthisiology, Pirogov Russian National Research Medical University, Moscow, Russia Background: Hematotoxicity and peripheral neuropathy are the most serious adverse events when using linezolid, which can lead to changes in the dose and treatment regimen of patients with multidrug-resistant tuberculosis. More often, toxic reactions occur with prolonged use, especially at a dose of 1200 mg. The aim of the study was to study in an experiment on rats the dependence of changes in markers of peripheral neuropathy and signs of hematotoxicity on the amount of the applied dose of linezolid. Materials and Methods: Inbred female rats were divided into two experimental and 1 control group of 10 individuals each. Linezolid was administered orally to rats daily for 14 days in a single dose of 54 (1 experimental group) and 108 (2 experimental group) mg/kg, which is equivalent to doses of 600 mg and 1200 mg for humans, respectively. The rats in the control group received an oral solvent (0.9% sodium chloride solution). The follow-up was continued for 30 days after the course of injections. After the 8th and 14th administration and on the 15th and 30th days after the end of the administration period, blood was taken from rats for clinical analysis and biochemical examination. Creatine kinase (KK), cholinesterase (HE), and lactate dehydrogenase (LDH) were determined as markers of peripheral neuropathy. Results: When linezolid was administered at a dose of 54 mg/kg, a significant increase in the level of CE was observed in the blood serum of rats. There was also a tendency to increase creatinine clearance, but without statistically significant differences with the control. Administration of linezolid in a single dose of 108 mg/kg resulted in a statistically significant increase in all markers (CC, CE, and LDH). At the end of the experiment (30th day of follow-up), the creatinine clearance level in both experimental groups was higher than in the control group rats. The HE index in Group 1 rats decreased to the control values, and in Group 2 rats, it was lower than in the control. LDH values did not exceed the control limits. Clinical blood analysis showed that linezolid at a dose of 54 mg/kg did not cause significant changes in the peripheral blood of rats. In Group 2 rats, after a course of linezolid injections at a dose of 108 mg/kg, there was a significant decrease in erythrocytes, hemoglobin, and hematocrit compared with the control, followed by normalization of these indicators by the 15th day of follow-up. Conclusion: Linezolid at a dose of 108 mg/kg, even with a short course of use, leads to the development of anemia in rats. At the same time, 15 days after the course, spontaneous recovery of blood parameters occurs. Significant changes in peripheral neuropathy markers were noted in rats of both groups, but were more pronounced when the drug was administered at a dose of 108 mg/kg and persisted for 30 days after its withdrawal. Keywords: Hematotoxicity, linezolid, neurotoxicity, rats relevance Conflicts of interest There are no conflicts of interest

Fields of Study & Subjects

Antibiotics Pharmacokinetics and Efficacy Tuberculosis Research and Epidemiology Cancer Treatment and Pharmacology

Publication details

Journal / source
International Journal of Mycobacteriology
Volume
15
Issue
Abstract Supplement
Pages
S58–S58
Publication date
1 March 2026
Language
EN